NF1 Mutations Prevalent but Not Clinically Relevant.
Whole-exome sequencing of 213 tumor samples shows that NF1 is mutated in 13.1% of melanomas. The gene is usually mutated in tumors that don't carry mutations in BRAF or NRAS, and it may be a cancer driver. However, loss of the gene didn't predict whether RAS activity increased or whether cell lines responded to inhibitors of the MAP kinase pathway, which RAS activates.